Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

Increased expression of ADAM12 and ADAM17 genes in laser-capture microdissected breast cancers and correlations with clinical and pathological characteristics

(2011) Diana Narita et al.   ACTA HISTOCHEMICA

Genotypic and Phenotypic Characterization of Side Population of Gastric Cancer Cell Lines

(2011) Rosa Schmuck et al.   AMERICAN JOURNAL OF PATHOLOGY

Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNF /NF B pathway

(2011) H. Armanious et al.   BLOOD

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Cross-domain inhibition of TACE ectodomain

(2011) C. J. Tape et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17

(2011) Thorsten Maretzky et al.   Nature Communications

Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression

(2010) J-W Kornfeld et al.   BRITISH JOURNAL OF CANCER

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation

(2010) Xuguang Zheng et al.   CANCER BIOLOGY & THERAPY

ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer

(2010) A. Baumgart et al.   CANCER RESEARCH

Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17

(2010) S. Van Schaeybroeck et al.   CANCER RESEARCH

Pathological Neovascularization Is Reduced by Inactivation of ADAM17 in Endothelial Cells but Not in Pericytes

(2010) Gisela Weskamp et al.   CIRCULATION RESEARCH

ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers

(2010) G. Sinnathamby et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma

(2010) A. Stokes et al.   CLINICAL CANCER RESEARCH

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

(2010) J. N. Kyula et al.   CLINICAL CANCER RESEARCH

The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: Novel drug targets with therapeutic potential?

(2010) Paul Saftig et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Inhibition of the Inflammatory Cytokine TNF-α Increases Adenovirus Activity in Ovarian Cancer via Modulation of cIAP1/2 Expression

(2010) Michael A Salako et al.   MOLECULAR THERAPY

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

(2010) Merel Gijsen et al.   PLOS BIOLOGY

Involvement of a disintegrin and metalloproteinase 10 and 17 in shedding of tumor necrosis factor-α

(2009) Atsuhiko Hikita et al.   Biochemistry and Cell Biology

Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands

(2009) Motomichi Nakagawa et al.   CANCER SCIENCE

Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts

(2009) Renata Mężyk-Kopeć et al.   CYTOKINE

Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia

(2009) Alexandra Szalad et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer

(2008) E. R. Brown et al.   ANNALS OF ONCOLOGY

Synergistic Inhibition with a Dual Epidermal Growth Factor Receptor/HER-2/neu Tyrosine Kinase Inhibitor and a Disintegrin and Metalloprotease Inhibitor

(2008) L. Witters et al.   CANCER RESEARCH

VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling

(2008) Steven Swendeman et al.   CIRCULATION RESEARCH

Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

(2008) Marcia L Moss et al.   Nature clinical practice. Rheumatology